HOSPIRA GLYCERYL TRINITRATE CONCENTRATE INJECTION glyceryl trinitrate 50mg/10mL Injection ampoule

Country: Australia

Language: English

Source: Department of Health (Therapeutic Goods Administration)

Active ingredient:

glyceryl trinitrate

Available from:

Pfizer Australia Pty Ltd

INN (International Name):

glyceryl trinitrate

Authorization status:

Registered

Patient Information leaflet

HOSPIRA
TM GLYCERYL TRINITRATE
CONCENTRATE INJECTION
Glyceryl Trinitrate _ (GLIS-er-ile tri-NITE-rate)_
CONSUMER MEDICINE INFORMATION
_Date of Dispensing_
_ _
_Consumer Name _
_Pharmacist Name _
_Consumer Address _
_Pharmacist Address _
WHAT IS IN THIS LEAFLET
This leaflet answers some
common questions about
Hospira
TM
Glyceryl Trinitrate
Concentrate Injection (glyceryl
trinitrate).
It does not contain all the
available information.
It does not take the place of
talking to your doctor or
pharmacist.
All medicines have risks and
benefits. Your doctor has weighed
the risks of you being given
glyceryl trinitrate against the
benefits they expect it will have for
you.
IF YOU HAVE ANY CONCERNS ABOUT
BEING GIVEN THIS MEDICINE, ASK
YOUR DOCTOR OR PHARMACIST.
KEEP THIS LEAFLET IN A SAFE PLACE.
You may need to read it again.
WHAT HOSPIRA
TM
GLYCERYL TRINITRATE
CONCENTRATE INJECTION
IS USED FOR
Glyceryl trinitrate belongs to a
group of medicines called nitrates
or vasodilators. It relaxes the
muscles surrounding blood
vessels (arteries and veins) and
so helps more blood and oxygen
reach the heart. It is also used to
control or lower the blood
pressure during some surgical
procedures.
Your doctor may have prescribed
glyceryl trinitrate for another
reason. Ask your doctor if you
have any questions about why
glyceryl trinitrate has been
prescribed for you.
Glyceryl trinitrate is not addictive.
This medicine is available only
with a doctor’s prescription.
Glyceryl trinitrate is not
recommended for use in children,
as there is not enough information
on its effects in children.
BEFORE YOU ARE GIVEN
HOSPIRA
TM GLYCERYL
TRINITRATE CONCENTRATE
INJECTION
_WHEN YOU MUST NOT BE _
_GIVEN IT _
YOU SHOULD NOT BE GIVEN
HOSPIRA
TM GLYCERYL TRINITRATE
CONCENTRATE INJECTION IF YOU
HAVE AN ALLERGY TO GLYCERYL
TRINITRATE OR ANY OF THE
INGREDIENTS LISTED AT THE END OF
THIS LEAFLET.
Symptoms of an allergic reaction
to glyceryl trinitrate may include:
•
shortness of breath, wheezing
or difficulty breathing
•
swelling of the face, lips,
tongu

Summary of Product characteristics

Product Information
Version 2.0
Page 1
PRODUCT INFORMATION
HOSPIRA™ GLYCERYL TRINITRATE CONCENTRATE INJECTION
NAME OF THE MEDICINE
Glyceryl trinitrate
Its chemical formula is C
3
H
5
N
3
O
9
, molecular weight is 227.1, and CAS registry number is 55-63-0.
The chemical structure of glyceryl trinitrate is shown below:
CH
2
ONO
2
I
CHONO
2
I
CH
2
ONO
2
DESCRIPTION
The chemical name of glyceryl trinitrate is propane-1,2,3-triol
trinitrate.
Glyceryl trinitrate is a white to pale yellow, thick, flammable,
explosive liquid. It is slightly soluble in
water, and soluble in acetone, alcohol, carbon disulphide, chloroform,
dichloromethane, ether, ethyl
acetate, glacial acetic acid and methanol.
Hospira™ Glyceryl Trinitrate Concentrate Injection is a sterile,
clear, practically colourless solution for
intravenous infusion after dilution. Each millilitre of Hospira™
Glyceryl Trinitrate Concentrate Injection
contains 5 milligrams of glyceryl trinitrate, absolute ethanol and
propylene glycol in Water for
Injections.
PHARMACOLOGY
Glyceryl trinitrate, an organic nitrate, is a vasodilator. Its
principal pharmacological action is the
relaxation of vascular smooth muscle. Glyceryl trinitrate produces a
dose related dilation of both
arterial and venous beds. Venous dilation predominates over dilation
of the arterioles. Dilation of the
post-capillary vessels, including large veins, promotes peripheral
pooling of blood and decreases
venous return to the heart, reducing left ventricular end-diastolic
pressure and pulmonary capillary
wedge pressure (pre-load). Arteriolar relaxation reduces systemic
vascular resistance and arterial
pressure (after-load). Glyceryl trinitrate also dilates the coronary
arteries, although this effect is short
lived.
Myocardial oxygen consumption or demand (as measured by the
pressure-rate product, tension time
index and stroke work index) is decreased by both the arterial and
venous effects of glyceryl trinitrate,
and a more favourable supply demand ratio can be achieved.
Therapeutic doses of intravenou